EGFR and non-small cell lung carcinoma: In addition to mutations, overexpression of EGFR was then observed to promote cancer progression, first in carcinomas [13,14], and later on in sarcomas [15], non-small cell lung cancer (NSCLC) [16] and malignant gliomas [17].